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ABSTRACT 
Giant cell arteritis (GCA) is a disease affecting medium-sized and large 
arteries in middle-aged or older persons. One purpose of this thesis was to 
describe the phenotypes of mononuclear cells infiltrating the temporal 
arteries of GCA patients. The expression of immunological activation markers 
on these cells and cm vascular smooth muscle cells was also studied. The 
mononuclear cell infiltration wets mainly cctnposed of T-helper lymphocytes 
(CD4) and macrophages. About one-fourth of the infiltrating T lymphocytes 
expressed the MHC class II antigen HLA-ER, probably indicating immunological 
activation. Arterial smooth muscle cells did not express HLA-ER antigen. For 
cccparison with these findings, the phenotypes of circulating T lymphocytes 
were studied in patients with GCA before and after 6-10 days of prednisolone 
treatment. The proportions of T lymphocytes, T-helper/inducer and T-
suppressor/cytotoxic cells before treatment did not deviate from those in 
normal individuals. On average, six per cent of the circulating T 
lynphocytes expressed the HIA-ER antigen. The number of T-helper cells 
expressing HIA-ÖR and IL 2 receptor was not changed by the treatment given. 
A second purpose of this thesis was to describe the morbidity and mortality 
in GCA patients receiving long-term corticosteroid treatment. A follow-up 
investigation of 90 patients with GCA was performed 11.3 years (median 
period) after diagnosis.The median duration of corticosteroid treatment was 
5.5 and 2.3 years, respectively, for wcman and men. The incidences of 
diseases possibly related to corticosteroid treatment, such as diabetes 
mellitus, hip fractures or peptic ulcer, were not increased in the GCA 
patients as oocpared to the general population. Furthermore, these treated 
patients shewed no increase in overall mortality or mortality from vascular 
diseases. However, GCA can be a threat to life due to engagement of cerebral 
and coronary arteries as well as of the aorta. This is seen in the initial 
phase of the disease and during insufficient corticosteroid treatment, which 
is illustrated by nine fatal cases, reported in detail. 
The observations suggest that cell-mediated immunological mechanisms are 
involved in the pathogenesis of GCA and that long-tens corticosteroid 
treatment is safe, effectively relieves synptcms, and prevents vascular 
ccraplications otherwise associated with the disease. 
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ABSTRACT 
Giant cell arteritis (GCA) is a disease affecting medium-sized and large 
arteries in middle-aged or older persons. One purpose of this thesis was to 
describe the phenotypes of mononuclear cells infiltrating the temporal 
arteries of GCA patients. The expression of immunological activation markers 
on these cells and on vascular smooth muscle cells was also studied. The 
mononuclear cell infiltration was mainly composed of T-helper lymphocytes 
(CD4) and macrophages. About one-fou rth of the infiltrating T lymphocytes 
expressed the MHC class II antigen HLA-ÖR, probably indicating immunological 
activation. Arterial smooth muscle cells did not express HLA-ER antigen. For 
canparison with these findings, the phenotypes of circulating T lymphocytes 
were studied in patients with GCA before and after 6-10 days of prednisolone 
treatment. The proportions of T lymphocytes, T-helper/inducer and T-
suppressor/cytotoxic cells before treatment did not deviate fror, those in 
normal individuals. On average, six per cent of the circulating T 
lymphocytes expressed the HLA-ER antigen. The number of T-helper cells 
expressing HLA-ER and IL 2 receptor was not changed by the treatment given. 
A second purpose of this thesis was to describe the morbidity and mortality 
in GCA patients receiving long-term corticosteroid treatment. A follow-up 
investigation of 90 patients with GCA was performed 11.3 years (median 
period) after diagnosis.Ohe median duration of corticosteroid treatment was 
5.5 and 2.3 years, respectively, for women and men. The incidences of 
diseases possibly related to corticosteroid treatment, such as diabetes 
mellitus, hip fractures or peptic uloer, were not increased in the GCA 
patients as compared to the general population. Furthermore, these treated 
patients showed no increase in overall mortality or mortality fron vascular 
diseases. However, GCA can be a threat to life due to engagement of cerebral 
and coronary arteries as well as of the aorta. This is seen in the initial 
phase of the disease and during insufficient corticosteroid treatment, which 
is illustrated by nine fatal cases, reported in detail. 
The observations suggest that cell-mediated immunological mechanisms are 
involved in the pathogenesis of GCA and that long-term corticosteroid 
treatment is safe, effectively relieves symptoms, and prevents vascular 
applications otherwise associated with the disease. 
Rev words: prognosis, mortality, corticosteroids, inrriunopathology, 
T lymphocytes, HLA-ER,smooth muscle cells, myocardial infarction, cerebral 
infarction,aortic aneurysm. 
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ABBREVDVnCIB 
ESR = Erythrocyte sedimentation rate 
G = General symptoms only in GCA 
GGA = Giant cell arteritis 
IFL = Immunofluorescence 
IL 2 = Interleukin-2 
MHC = Major histocompatibility ccsrplex 
MNC = Mononuclear cells 
NK-cells = Natural killer cells 
H4R = Polymyalgia rheumatica 
SMC = Smooth muscle cells 
T = Temporal arteritis 
TP = Temporal arteritis + polymyalgia rheumatica 
DEFDnnOE: Flare-up of the disease = syirptcms of the disease that 
necessitate an increase in the dose of ongoing corticosteroid 
treatment. 
Relapse of the disease = symptoms of the disease after 
withdrawal of treatment. 
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UTOißöüCnCN 
Giant cell arteritis is a disease with inflammation in medium-sized and 
large arteries, mainly affecting persons over the age of 50 years. The 
annual overall incidence of the disease in Göteborg has been calculated to 
be 9.3 cases per 100,000 inhabitants, but in the ages over 50 years the 
incidence is 28.6 per 100,000 (11). The disease is about twice as ccranon 
among wcmen. 
Up until the 1950s giant cell arteritis was usually divided into temporal 
arteritis and polymyalgia rheumatica. Porsman and Paulley then realised that 
the two conditions were clinically inseparable and merely two expressions of 
the same disease, including a more or less generalised arteritis (120,122). 
Ulis has been confirmed by marry authors during the last decades (1, 12, 34, 
44, 63, 66, 78, 130, 140). 
Ihe name giant cell arteritis was first used fcy Gilmour in 1941 (40). In 
this thesis the term "giant cell arteritis" is used for the disease, 
including both tenporal arteritis and polymyalgia rheumatica. 
Histopatholoqy 
The histopathological picture of giant cell arteritis has been well known 
since the descriptions in the 1930s by Horton (52, 53) and by Gilmour in 
1941 (40). The arterial wall presents an infiltration of mononuclear cells 
concentrated around the inner half of the media centering upon the frag­
mentai internal elastic membrane. A more severe inflammation may continue 
throughout the outer half and adventitia as well. Giant cells are frequently 
tut not always seen. Luminal constriction may occur in severe cases. Elect-
ron-microsccpic examination of the arteries has confirmed the lightmicro-
scopic findings and has added information about the smooth muscle cells, 
demonstrating degenerative changes with swelling of the mitochondrias and 
vacuoles in the cytcplasma (123). 
Pathogenesis 
Marry hypotheses concerning the pathogenesis of GCA have been presented since 
Hutchinson's suggestion in 1890 that the pressure fron the hat may cause the 
disease (59). O'Brien thought infrared irradiation could cause the disease 
by transcutaneous damage to the elastin (108). The influenza-like onset of 
the disease has prompted a search for a viral aetiological agent. Hepatitis 
B as a trigger for MR was suggested by Bacon (5) but other studies (19, 30, 
85) have not confirmed the observation of an increased prevalence of 
8 
hepatitis B antibodies among GCA patients. 
Among infectious diseases, long-lasting polymyalgia has been described in 
yersiniosis (112). Fessel (37) found that 46 per cent of patients with FMR 
or temporal arteritis had had significant contact with pet birds, particu­
larly parakeets, compared to 26 per cent of controls, but later studies 
(111, 137) have not confirmed these results. 
Degradation of elastic fibres in the arterial wall in GCA was observed in 
1952 by Kimme].,stiel and co-workers. (71). The striking localisation of the 
inflammation around the internal elastic lamina has given rise to the theory 
of a reaction against elastin as the pathophysiological mechanism. If 
heterologous elastin is inplarrted in the subcutis or peritoneum of rats, the 
cellular infiltration begins with neutrophils, continues with lynphocytes, 
fibroblasts and macrophages and ends with the formation of giant cells 
(116). Further support is the finding of linear deposits of leukocyte 
elastase along the fragmented internal elastic membrane (136). However, no 
antielastin antibodies have been found in serum of GCA patients (57), and in 
electron-microscopic studies no signs of phagocytosis of elastin were 
observed (24, 119). 
It is also possible that the observed histopathological changes reflect a 
non-specific reaction to injury, regardless of the cause of the disease. 
This hypothesis is supported by the finding of similar changes after 
experimental dilatation injury of the carotid arteries in rabbits (124). 
Immunological features have been studied extensively in patients with GCA. 
Deposition in the arterial wall of immunoglobulin and complement in the 
majority of the patients has been found by some authors (84, 117, 127, 135, 
136) but not by otters (6, 25, 39, 123). Waaler and co-workers (135) 
demonstrated anti-iimnunoglcbulin in the arterial wall. Increased levels of 
circulating imnune complexes have been observed in seme studies (14, 33, 
115, 118, 143) but not in others (93). 
Hazleman observed that lymphocytes front patients with FMR shewed higher 
transformation responses to arterial antigens than lynphocytes from controls 
(49). This observation has, however, not been confirmed by others (93, 114, 
146). 
Further support for the involvement of iitsnunological mechanisms in the 
pathogenesis of GCA was the finding of an increased prevalence of the major 
histocompatibility catplex (MHC) antigens HLA-DR3, HLA-DR4 or HLA-DR5 (2, 7, 
92) in patients with GCA. A high prevalence of these antigens is associated 
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with disorders that have an autoimmune basis (92). 
Not until recently have techniques been developed that allcw cellular 
interactions to te studied in situ. The development of the monoclonal 
antibodies 'which recognise functional suhpcpulations of lymphoid cells has 
been a major advance (79). During the last few years, a wide variety of 
monoclonal antibodies have become commercially available, giving us a new 
opportunity to characterise the cells in both tissue and blood. Regarding 
GCA, only a few previews studies have been published, with conflicting 
results (6, 14, 23, 25, 31). 
Treatment of GCA 
Corticosteroid treatment in GCA was first reported in 1950 (129). An 
excellent therapeutic response was soon recognised and found to be an almost 
diagnostic feature. The duration of treatment and the risk of corticosteroid 
side effects has been evaluated in several reports (3, 9, 10, 26, 27, 36, 
50, 58, 76, 130), most of them based on relatively small patient groups or a 
short time of observation. The reported average duration of the treatment 
ranges from seven months (58) to six years (36). The most cannon cortico­
steroid side effects suggested are diabetes mellitus, hip fractures, 
vertebral crush fractures, peptic ulcer and cataract, but the prevalences of 
these complications vary widely in the available studies. 
Mortality in GCA 
GCA is a generalised arteritis involving large and medium-sized arteries. 
EXje to engagement of the. cerebral and coronary arteries and the aorta, the 
disease can be a threat to life. Hcwever, only a few fatal cases are 
reported in the literature and most clinicians are probably not aware that 
GCA can cause cerebral and myocardial infarction as well as aortic aneu­
rysms. 
In most hospitals, microscopic examination of the coronary and cerebral 
arteries is not routinely performed at autopsies of patients with fatal 
myocardial and cerebral infarctions. Nor is the aortic wall studied in 
detail in most patients with ruptured aneurysms. The real prevalence of 
fatal GCA is thus not known, but in most studies the overall mortality rates 
among corticosteroid-treated patients are similar to those in the general 
population (26, 41, 42, 47, 58, 64, 77). 
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AIMS OF THE STOCK 
The main purposes of this study of GCA patients were: 
- To characterise the phenotypes of infiltrating mononuclear cells in the 
temporal arteries of patients with GCA and to evaluate the expression of 
immunological activation markers on these cells. 
- To ascertain whether there is iinrnanohistological evidence for engagement 
of the smooth muscle cells in the inflammatory process in the temporal 
arteries. 
- To determine the prevalence of immunological activation markers on 
T lymphocytes in the blood. 
- To evaluate the long-term mortality and morbidity in corticosteroid-
treated patients. 
- To describe the occurrence of fatal GCA in vital arteries. 
PATHNES AND METHODS 
Patients 
Altogether 138 patients with GCA were studied. 
Ninety patients (68 wctnen and 22 men) were diagnosed as having GCA between 
1968 and 1975 at the Department of Medicine III, Sahlgrenska Hospital, and 
the Department of Infectious Diseases, östra Hospital, Goteborg. Their mean 
age at diagnosis was 72 years (range 52-86 years). The results of a follow-
up examination in 1979 have been presented in a thesis by Bengtsson and 
Malmvall in 1982 (13). A long-term follcw-up investigation was performed 
between January and September 1985, resulting in papers III and IV. A median 
time of 11.3 years had then elapsed since diagnosis. All patients were 
traced and medical records of outpatient and hospital care were studied for 
all 90 patients. During the observation period, 43 patients died (28 women 
and 15 men). Their irean age at death was 82.5 years. The 47 patients alive 
at the time of follow-up had a mean age of 79.8 years. Forty-two of than 
were medically examined and questioned. 
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In papers I and II, thirteen women with histologically vérifiai GCA were 
compared with six women with GCA but negative histological findings and 
seven patients (four woman and three men) with other, unrelated, diseases. 
In paper II, the biopsies of the temporal arteries frcm an additional eleven 
patients (nine worsen and two men) with GCA were cotpared with biopsies from 
three wcmen with unrelated diseases. In paper II, blood saitples were 
obtained frcm a new patient group of six women and four men with GCA. 
Nine patients with GCA as a cause of death were collected frcm the depart­
ments of pathology in Göteborg between 1978 and 1984 and aire presented in 
paper V. One of the patients belonged to the series of 90 patients presented 
in papers III and IV. 
The patients were divided into the following four clinical groups: 
I. Temporal arteritis IT): patients with symptoms frcm the temporal region 
such as headache, scalp tenderness, jaw claudication and tenderness and 
swelling of the temporal artery. 
II. Polymyalgia rheumatica (FMR) : patients with proximal muscle symptoms of 
pain and morning stiffness without signs of inflammatory arthritis. 
III. Temporal arteritis and polymyalgia rheumatica (TP'i ; patients with both 
symptoms from the temporal area and polymyalgia rheumatica. 
IV. General symptoms (G) : patients with no clinical symptoms frcm the 
temporal region or proximal muscles but with constitutional symptoms such as 
fever, fatigue and malaise. All the patients in this group had a histolo­
gically proved arteritis. 
Diagnostic criteria for GCA 
Patients were diagnosed as having GCA if a tenporal artery biopsy shewed 
arteritis, characterised by the histological findings of interruption of the 
internal elastic membrane with infiltration of mononuclear cells in the 
arterial wall. Giant cells were often found but their presence was not 
required for diagnosis. 
In patients with negative histological findings, the diagnosis of GCA was 
accepted if they fulfilled the following clinical criteria: 
Pain and stiffness affecting at least two large groups of proximal muscles 
(i.e. neck, shoulders - upper arms, hips and thiols) with duration of 
syitptoms of more than two weeks and without evidence of inflammatory 
arthritis. 
Elevated erythrocyte sedimentation rate (ESR) above 40 mn^/h and an age of 50 
years or more. 
No clinical or laboratory evidence of infection, malignant disease, 
rheumatoid arthritis, systemic lupus erythematosus or periarteritis nodosa. 
A prcrapt and long-lasting relief of symptoms after institution of cortico­
steroid treatment. 
Immunchistochemical methods 
Temporal artery specimens were studied from altogether 40 patients. Twenty-
one of the biopsies showed histological signs of GCA on examination by 
routine light microscopy. Nine patients had GCA according to clinical 
criteria but a negative biopsy. As controls, we used eleven biopsies from 
ten patients who proved to have other unrelated diseases. 
The specimens were rapidly frozen and stored at -70°C. 
Six-micron-thick serial sections from the arteries were prepared in a 
cryostat, They were then analysed either by immunoperoxidase (paper I) or 
double immunofluorescence (paper II) technique. 
Antibodies 
ïhe following monoclonal antibodies were used (see also table I) : 
Anti-Ii3u 4 reacts with the T-cell antigen CD3, present on all T lymphocytes 
(56). 
Anti-Leu 3a and 3b is directed against the CD4 antigen present on T-
helper/inducer lymphocytes (81). In addition, seme of the monocytes and 
macrophages may react weakly with the antibody (142). 
Anti-Leu 2a is directed against the CDS antigen present on the suppressor-
/cytotoxic T-cell subset (81). 
1 3  
Table I. Antibodies used in the innurKiiistxxiianical study of GCA 
Name Specificity Produced in Supplier 
Monoclonal antibodies 
Anti-Leu 4 CD3, all T lynphocytes mouse 
Anti-Leu 3a+b 
Anti-leu 2 
Anti-leu M3 
Anti-leu 12 
Anti-HLA-CR 
Anti-HLA-DR 
YE2.36 
Anti-transferrin 
reœptor 
Anti-Interleukin-2 
reœptor 
CD4, T-helper/inducer 
lymphocytes, scms macro­
phages and monocytes mouse 
CD8, T-cytotoxic/suppressor 
lymphocytes mouse 
CD14, monocytes and mouse 
macrophages 
CD19, all B lymphocytes mouse 
MHC class II antigen HLA-ER mouse 
_n_ 
-"- rat 
Transferrin receptor mouse 
CD25, interleukin-2 receptor mouse 
A 
A 
C 
E 
D 
Polyclonal antibodies 
Anti-asialo GM1 Natural killer (NK) cells rabbit 
Anti-smooth muscle Heavy chain of smooth muscle rabbit 
myosin myosin 
B 
F 
Suppliers: 
A = Becton and Dickinson, Sunnyvale, CA, USA 
B = Wako, Osaka, Japan 
C = Dakopatts, Glostrvq?, Denmark 
D = Sera-lab, Crawley-Dcwn, Sussex, U.K. 
E = Atlantic antibodies, Scarbourogh, Maine, USA 
F = Dr EM Larson, Boston University, Mass. USA 
u 
Anti-lea M3 is directed against the CD14 antigen. It labels monocytes arid 
macrophages (29). 
Anti-Leu 12 reacts with the CD19 antigen present on all B lymphocytes (98). 
Anti-HLA-DR reacts with the MHC-class II antigen HIA-OR (4). 
YE2.36 is directed against the HLA.-ER antigen (18). 
Anti-transferrin receptor The expression of the transferrin receptor has 
been found to correlate with the proliferative status in both normal and 
malignant mononuclear cell populations (134). 
Anti-Interleukin-2 receptor reacts with the CD25 antigen that is associated 
with high affinity binding of interleukin-2. Interleukin-2 receptor 
expression is a prerequisite for subsequent IL 2 binding and activation of 
T-cells (82). 
Two polyclonal antibodies were used (Table I): 
Anti-smooth muscle myosin reacts with the smooth muscle specific form of the 
heavy chain of myosin (80). 
Anti-asialo-CT41 identify the natural killer (NK)-cells (69). 
In the imiminoperoxidase technique, the sections were incubated with the 
monoclonal antibodies using biotin-labelled species-specific anti-immuno-
globulin as the secondary reagent. Binding of biotin-labelled antibodies was 
detected after incubation with avidin-biotin-peroxidase ccnplexes (55) (Fig. 
1) and subsequent use of H2C>2 and a buffer containing 3-amino-9-ethyl-
carbazol. The sections were counterstained with Mayers' haematoxylin and 
studied under a light microscope. 
Figure 1 
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Reprinted with permission 
fran 
Bourne JA: Handbook of 
Iimtuncperoxidase staining 
methods. Dako corporation 
1983. 
Secondary Antibody 
In the double immunofluorescence technique, the cryostat sections were first 
incubated with monoclonal antibodies against HIA-ER, followed by species-
specific biotinylated anti-IgG and FITC-streptavidin. They were then 
incubated with anti-myosin or IÊU 4 and finally species-specific rhodamine-
labelled arrti-IgG. The sections were studied under a fluorescence microscope 
with interference filters for fluorescein and rhodamine. 
All antibodies were used at optimal dilutions, which were determined by 
checkerboard titrations on peripheral blood smears, lymph nodes or athero­
sclerotic plaques. 
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A fluorescence-activated cell sorter (FACS) was used for study of the T-
subsets and markers of iiiinunological activation in peripheral blood. 
The surface expression of antigens on peripheral blood lymphocytes was 
determined by quantitative two-colcur analysis with a FACS tar (Becton-
Dickinson, CA, USA). Forward (i.e. size) and right-angle (i.e. granulation) 
scatter gates were set on lynphocytes excluding monocytes and other 
leukocytes. Analysis was performed on 10 000 cells frcm unseparated 
heparinised blood using Fluorescein 5-Isothiocyanate (FITC) or R-Phyco-
erythrin-conjugated monoclonal antibodies. 
Statistics 
The expected number of deaths in the GCA patients was calculated by adding 
mortality risk rates obtained frcm the official Swedish statistics (87) for 
each month of observation for each patient, until death or until January 
1985. Death rates for vascular, malignant and infectious diseases were 
compared with data fron officiell Swedish statistics (133). Statistical 
comparisons of observed and expected mortality were made by vising signi­
ficance limits for the Poisson distribution. 
For calculation of the madian duration of corticosteroid therapy we used a 
life-table method. For statistical comparisons, we used the univariate chi 
squares for log rank test (68). 
For comparing the T-subsets in blood before and after treatment with 
prednisolone, we used Fischer's two-sided test for pair comparisons. 
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RESILIES AND DISOJSSICSI 
Imniunohistochemical findings (papers I and II) 
Almost all the lymphocytes in the arteritic lesions of patients with giant 
cell arteritis expressed the T-cell phenotype. No or very few B-cells were 
found. In all patients, the T-helper/inducer (CD4)-subset dominated over the 
T-saçpressor/cytotoxic (CDS) -subset. A lew number of natural killer (NK) 
cells was detected in the arterial wall from most GCA patients and controls. 
In all the biopsies with signs of arteritis, we also found an infiltration 
of macrophages. Usually, the number of macrophages was slightly lower than 
the number of lymphocytes. The mononuclear cells (MNC) in 11 out of the 13 
positive biopsies shewed staining for HIA-ER antigen using the immunoperoxi-
dase technigue. With the double imnunofluorescenoe method, macrophages and 
lymphocytes expressing the HLA-DR antigen were found in 20 out of 21 
positive biopsies, The relative number of infiltrating T-cells expressing 
the HLA-ER antigen was on average 28% (range 16-42%). In 6 out of the 11 
control biopsies expression of HLA-DR antigen was infrequently observed. 
CXir findings are in agreement with those of Banks and co-workers (6), who 
observed a predominance of the T-helper/inducer subset and noted that the 
MNC expressed the HIA-ER antigen. In contrast, Chess and coworkers (25) 
found equal numbers of T-helper/inducer and T-suppressor/cytotoxic cells. 
The; human major histocompatibility complex (MHC)-class II antigens are HIA-
ER, -DQ, and -DP (4). The class II antigens are involved in the presentation 
of antigens, and a foreign antigen is only recognised by the T-helper 
lymphocyte if it is presented together with the class II antigens on the 
surface of an antigen-presenting cell (for review see 113). The interaction 
between the class II antigens, foreign antigen and the T-helper lymphocyte 
leads to an immunological activation of the T lymphocyte, which then 
expresses the interleukin-2 receptor and produces interleukin 2 (IL 2), as 
well as other lyitphokines. Among the activated T-helper lymphocytes, two 
sutpopulations can be recognised: one that stimulates B lyitphocytes to 
antibody production (103) and another one that induces cell-mediated immune 
responses (102). 
HLA-DR antigens are constitutively expressed on mature B lymphocytes and a 
sutpopulation of macrophages (60, review). "Die T lymphocytes, on the other 
hand, express HXA-ER antigens only in the activated state (60). The frequent 
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expression of HIA-DR antigens on the T lymphocytes in the arteritic lesions 
therefore indicates that immunological activation has taken place (94). 
Further support for a local activation of the T-cells was the finding of 
interleukin-2 receptors on the lynçhocytes in 6 cut of 13 biqpsies with 
signs of arteritis. The IL 2 receptor expression on the lymphocytes was not 
as frequent as the HIA-DR expression. The reason for this discrepancy is not 
known but the same pattern has been observed in other inflammatory lesions, 
such as salivary glands in sialoadenitis (67, 128) and synovial tissue in 
rheumatoid arthritis (20). The activated status of the T-cells was also 
demonstrated by the detection of transferrin receptors on lynçhocytes in 7 
out of 13 positive biopsies. 
It remains to be established whether homing of activated T-œlls into 
arteritic areas takes place or whether expression of HLA-DR antigen, IL 2 
receptor and transferrin receptor is induced in situ. 
Expression of HLA-ER can be induced in normally negative cells, e.g. on 
thyrocytes in Hashimoto's thyroiditis (62) and on glandular epithelial 
cells in Sjogren's syndrome (88). Such an abberant expression of HIA-DR on 
vascular smooth muscle cells has been reported both in studies on athero­
sclerosis in this laboratory (46, 65) and in vasculitis in the MRI/~lpr 
mouse model (105). 
By means of the double-staining immunofluorescence technique, we stained the 
temporal artery biopsies in the patients with GCA for HIA-DR antigen and 
myosin. A strong staining for myosin, detecting the smooth muscle cells, was 
found in the arterial walls but without any concomitant staining for HIA-DR. 
The results indicate that the immunopathogenetic mechanisms are different in 
giant cell arteritis on the one hand and atherosclerosis and MRL/~lpr 
vasculitis on the other. 
Our results suggest that a cell-mediated immune reaction, possibly against 
an autologous antigen, is occurring locally in the arteritic lesions of GCA. 
The observed HIA-DR expression in the arterial wall can be accounted for by 
the sum of macrophages and activated T-cells, the macrophages being the most 
probable antigen-presenting cells. What the antigen(s) may be is, however, 
still unkncwn, as are the factors initiating the process. 
The iramunciiistoGhemical pattern, with a predominance of T-helper/inducer 
cells surrounding HIA-ER-expressing cells, represents a common immune 
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reaction in nan and has teen found in several different conditions, not only 
in diseases with a putative autoimmune pathogenesis, e.g. rheumatoid 
arthritis (89), Hashimoto's thyroiditis (62), sialadenitis (Sjogren's 
syndrome) (88, 128) and myositis (110), tut also in synovitis due to trauma 
or ^ crystals (89), osteoarthritis (90), thyrotoxicosis (62) and atherosclero­
sis (65). 
Circulating T Ivmchocvtes (paper II) 
The proportions of T lymphocytes, T-helper/inducer and T-suppressor/cyto™ 
toxic cells were within the normal range in the blood from 10 patients with 
GCA before treatment with corticosteroids. The results are in agressent with 
those of Banks and co-workers (6) but in contradiction to previous reports 
of a selective decrease of T-suppressor/cytotox i c cells in GCA (14, 23, 31). 
The latter studies conflicting with our results were performed on separated 
mononuclear cells, which may cause changes of the T-cell ratios during 
preparation (61). In addition, all but Banks and coworkers (6) utilized 
manual reading by microscope, which may be a less sensitive method for 
detecting fluorescence. 
In contrast to the high prevalence of HLA-ER expression on the T lyitphocytes 
in arterial wall, only 2-14 per cent (mean 6%) of the T-helper/inducer 
cells and 0-10 per cent (mean 6%) of the T-suppressor/cytotoxic cells in 
the blood expressed the HIA-DR antigen. This is about the same as in 
healthy normal individuals with reported mean values for HLA-EK expression 
on T lymphocytes of 2.4-7.4% (21, 139, 145). As rheumatoid arthritis can be 
a differential diagnosis for GCA, it is of interest to note that the 
population of T-cells expressing HLA-DR exceeded 20% in one-third of the 
patients with rheumatoid arthritis (145). 
All the patients were treated with prednisolone 30-50 mg daily and after 6-
10 days we found a minor increase of the T-helper/inducer (CD4) subset from 
0.5-2.3 (mean 1.3) x 109/1 to 0.8-3.7 (mean 1.9) x 109/1. Ihe increase was 
statistically significant (p=0.04). The number of T~suppressor/cytotoxic 
(CD?) cells was not changed. The CD4/CD8 ratio thus increased by on average 
0.8 (p=0.002). 
Corticosteroids are known to cause a transient lymphocytopenia (35, 48, 
144), especially decrease of the T-helper cells (48). The lowest values of 
T-helper cells are seen about four hours after administration of cortisone, 
with a slight rebound increase after 24 hours (48). This can explain the 
20 
observed increase of T-helper cells in cur patients, as the blood samples 
were obtained in the morning about 24 hours after the last prednisolone 
dose. 
rflie absolut e number of T-helper cells expressing HLA-ER antigen was not 
altered after 6-10 days of treatment with prednisolone. Interleukin-2 
receptors were detected on 0-4 per cent (mean 1%) of the circulating T-
helper cells before treatment, with no statistically significant changes 
elfter prednisolone was given. 
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Effects of lom-term corticosteroid treatment (paper III) 
D^ sge_and_duratiori of_cgrticc§teroid treatment 
Ficaire 2 
PROBABILITY O F CO NTIMJED C ORTICOSTEROID T HERAPY 
T 1 1—-r——t——i 1—•—i r—i 1— 
0 1 2 3 4 5 6 7 8 9  1 0  (YEARS)  
T IME A FTER DIA GNOSIS  
WOMEN MEN 
Probability of 
continued cortico­
steroid therapy at 
different times after 
diagnosis in ninety 
patients with giant 
cell arteritis. 
Ninety patients (68 women and 22 men) were follcwed up after a median time 
of 11.3 years frcm the time of diagnosis of GCA. All but one patient were 
treated with corticosteroids. Hie mean initial dose of prednisolone was 33.2 
mg (range 0-60 mg). The median duration of treatment was estimated, by using 
the life-table method, to be 5 years (fig. 2). 
Seventy-five per cent of the patients received treatment for two years or 
none and 23% for more than 10 years (Fig. 2). 
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Fifty per cent of the wcmen were still on treatment at 5.5 years from 
diagnosis, compared to 2.3 years for the men (p=0.06) (Fig. 2). A shorter 
duration of treatment for men has also been observed by Chuang (26) and 
Ayoub (3). 
No significant differences were found when the probability of continued 
corticosteroid therapy against time after diagnosis was compared for the 
four different clinical groups of GCA. 
Figure 3 shows the prednisolone dosage 1-9 years after diagnosis. Sixty 
patients were alive after nine years. Fifteen of them (25%) were on 
treatment with 1.25 mg-10 mg prednisolone (median 5 mg) daily. 
At the time of follcw-up examination, 8 out of 47 surviving (17%) patients 
were on treatment with prednisolone. They had been treated for 5.2-11.7 
(median 10.4) years. Ihe prednisolone dose was 2.5-7.5 (median 5) ntj daily. 
1 2 3 4 5 6 7 8 9  Y » a r s  
Figure 3 
Percentage of GCA 
p a t i e n t s  o n  
different doses of 
p r e d n i s o l o n e ,  
surviving 1-9 years 
after diagnosis in a 
series of orginally 
ninety patients. 
• No prednisolone W j >5 $75 mg prednisolone daily 
A >0<5mg prednisolone 
daily 
>75 mg prednisolone 
daily 
23 
Of the 43 patients who died during the observation period, 19 were on 
corticosteroid treatment at the time of death 0.3-13.3 (median 5.1) years 
after diagnosis. The prednisolone dose ranged from 2.5 to 20 (median 5) mg 
daily. 
the corticosteroid treatment makes the patients free from symptoms but no 
report suggests a shorter duration of the disease compared to untreated 
patients. 
In reports frcm Minnesota, the median duration of the treatment was found to 
be only 7 months for temporal arteritis (58). Similar to us, Healey noted 
that 42% of the patients were still taking steroids after 5 years (50), and 
Fernandez-Herlihy registered a mean duration of corticosteroid treatment of 
6 years (36). Ayoub reports a shorter median duration of treatment, 37 
months (3) and Cocmes observed that 84% of the patients still required 
steroids after 5 years (27). 
ïhese differences may be due to variations in sex distribution and to 
selection mechanisms in the countries and departments where the patients 
were collected. Oar results are based upon a large patient group and a long 
duration of observation ccttpared to the other studies. The patients were 
collected frcm the entire city of Göteborg without any obvious selection and 
the presented duration of GCA thus should represent a good estimate of the 
situation in the GCA-affected population. The duration of treatment observed 
by us differs frcm that described in many textbooks (8), which suggests that 
the needed duration of treatment usually is shorter. 
Relapse of_GCA 
Forty-nine relapses were registered after 104 atterrpts to withdraw the 
corticosteroid treatment in 72 patients. This gives an overall relapse rate 
of 47%. The rate is about the same regardless of the time after diagnosis 
when the attempt to withdraw the treatment was made. Nor was there any 
difference in relapse rate between the polymyalgia rheumatics and temporal 
arteritis groups. 
As demonstrated in table II, 46% of the relapses occurred within the first 
month and 67% within two months of the termination of treatment. Ninety-six 
per cent occurred during the first year. 
In 15 out of the 90 patients, no relapses or flare-ups were registered. 
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Table II Number of relapses in relation to tune after withdrawal of 
corticosteroid treatment in 72 patients with GCA 
Time after withdrawal (months) 
<1 >1<2 >2<6 >6<12 >12 Total 
Number of 22 10 8 
(46%) (21%) (17%) 
6 2 48 
(4%) (100%) relapses (12%) 
In other studies, the reported relapse rate after withdrawal of corticoste­
roids is 30 out of 72 (42%) (10), 13 out of 56 (23%) (34), 13 cut of 37 
(35%) (3) and no relapses (36). v. Knorring (76) observed that 26 out of 33 
relapses (79%) occurred within one month and Fauchald (34) reported 7 out of 
13 (54 %) relapses within three months after discontinuation of treatment. 
The conclusion must be that it is very important to observe the patient 
carefully during the first year after termination of the treatment. 
Flare-up_of GCA ^ ringLtreatment 
One hundred and fifteen flare-ups were registered in 48 patients. Forty-six 
per cent of them occurred within the first year of treatment. Thirteen per 
cent of the flair-ups were seen after more than five years and five per cent 
after more than seven years. Seventy-seven per cent of them were seen during 
treatment with 7.5 mg of prednisolone or less. The most ccsnmon symptom of 
flare-ups was muscular disccsnfort, regardless of which clinical group the 
patient belonged to at the time of diagnosis. 
Health condition of_the_patients at_follcw-up 
Despite their high age (mean age 80 years) most patients were in excellent 
condition at the follcw-up examination. Abcwt two-thirds coped with their 
activities of daily living without help. Thirteen per cent lived in insti­
tutions. Seventy-seven per cent read a daily newspaper. 
Three of the patients were blind, but due to other diseases than GCA. None 
of the patients had any synptcms or laboratory values indicating ongoing 
relapse or flare-up of the disease. 
Diseases_diagnos^_durjj)g the observation period 
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Table III Number of patients with different diseases diagnosed after GCA in 
a series of orginally ninety patients with a median follcw-iç frimp 
of 11.3 years 
Cause of 
N death fNÏ 
Malignant diseases 14 7 
Aneurysm of the aorta 6 2 
Myocardial infarction 13 6 
Cerebrovascular infarction 19 6 
Diabetes mellitus 10 1 
Hip fractures 8 
Compression fractures of the spine 6 
Gastric or peptic ulcer 6 
Cataract 18 
The recorded diseases in our ninety patients with GCA, daring a Median 
follcw-up period of eleven years, are listed in table III. 
The morbidity from malignant diseases appeared to be as expected conpared to 
the general population of the same age, which also has been reported by von 
Knorring (75) and Boesen (17). 
Among the vascular diseases, we observed six cases of aneurysm of the aorta 
in our 90 patients (7%). Ihe incidence of aortic aneurysms in Sweden is not 
known, but in a population study from Rochester, USA (99) the annual 
incidence of aortic aneurysms in 1971-80 between the ages of 70 and 79 years 
has been estimated to be 465 per 100 000 person-years for men and 115 per 
100 000 person-years for wcroen. With that incidence, only 2 cases of aortic 
aneurysms could be expected during the observation period in our patients. 
Ihe incidence of aneurysms among GCA patients thus seems to be increased 
compared to the general population. 
In an autopsy study, Östberg found aortic aneurysms in 11 out of 79 patients 
(14%) with GCA (147). Among the thoracic aortic aneurysms treated at a 
department of surgery, 5 out of 43 (12%) patients were found to have giant 
cell arteritis (131). Ihe possibility of GCA should be considered in all 
cases of aortic aneurysms and microscopic examination is reccamended on 
aortic specimens obtained during operation of aneurysms. 
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Ohe incidences of myocardial infarction and cerebrovascular disease are high 
even in the general population of elderly persons and a minor increase in 
morbidity is difficult to detect. In a population study from Göteborg (83), 
nine per cent of the men and eight per cent of the women suffered non-fatal 
myocardial infarction between 70 and 75 years of age. A few case reports on 
non-fatal giant cell arteritis in the coronary arteries (100, 121), aorta 
(74, 95, 109, 126, 131) and cerebral arteries (32, 91, 101, 141) have been 
published but the prevalence of GCA in vital arteries is not kncwn. 
torticosteroid_side effects 
In our 90 patients, we found 10 cases of diabetes mellitus during the median 
observation period of 11 years. A population study in Göteborg shows an 
annual incidence of diabetes mellitus of about 1% in men and women aged 70-
80 years (S. Iandahl, personal caramunication). ïhe observed diabetes 
incidence in our patients thus does not seem to be higher than in the 
general population. 
We found eight patients with fractures of the neck of the femur. Nilsson 
(107) reported an incidence of hip fractures in Stockholm in 1978 of 1,2 
per cent for women and 0,7 per cent for men at ages between 75 and 79 years. 
The observed incidence of hip fractures in our patients is thus about the 
same as expected. 
Compression fractures of the spine verified by X-ray am not known before 
treatment were found in 6 of the patients (all women) when even minor 
compressions were included. However, X-ray of the spine has been perf ormed 
only in a minority of the patients and the true incidence of compressi on 
fractures cannot be estimated. 
ïhe incidence of gastric or peptic ulcer and cataract among our patients was 
not remarkably high for a group of elderly persons. 
Setae authors recoronerri a trial of non-steroidal drugs for uncomplicated 
polymyalgia rheumatica, because of the risk of corticosteroid side effects 
(22, 26). A few studies report a high incidence of adverse reactions to 
corticosteroid therapy (42, 125). Most authors, however, report a relatively 
low rate of side effects like us (10, 27, 36, 76, 106). When evaluating the 
morbidity in a group of elderly perso ns like most patients with GCA, it is 
important to caipare the results with the morbidity in the general popula­
tion, as we have done in our study. None of the other reports includes such 
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an analysis of the side effects. 
Corticosteroid treatment is the only therapy proved to prevent blindness in 
GCA (15). We reooimend œrticosteroid treatment to all patients with GCA, 
regardless of clinical group. The duration of treatment must be 
individualised and can only be determined by trial and error. Ohe 
corticosteroid dosage should be the lewest one that controls the patient's 
synptans. The corticosteroid-treatment in GCA may be considered safe both 
with respect to significant adverse drug reactions and as regards 
complications of the GCA. 
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Mortality in GCA (Papers IV and V) 
Between 1978 and 1984 nine fatal cases of GCA were observed at the depart­
ments of pathology in Göteborg. Two of the victims were not knewn to have 
GCA until autopsy. For five of the patients the diagnosis was verified by 
temporal artery biopsy before death. Two patients had a clinical diagnosis 
of polymyalgia rheumatica years before death. Temporal artery biopsy had 
been performed in one of them without showing arteritis. 
The causes of death in the series of nine fatal cases were GCA in coronary 
arteries in two patients, GCA. in cerebral arteries in five and GCA causing 
aortic aneurysms in two cases. The causes of death and microscopical 
findings are summarised in table IV. 
o^cardial_ infarction 
We report two patients with GCA in the coronary arteries. One of them (case 
1) suffer«! from myocardial infarction on the fourth day of treatment and 
she died after a further week. Ohe other patient had been treated with 
prednisolone for three years because of polymyalgia reumatica. IXuring a 
flare-up of the disease, she developed myocardial infarction and progressive 
cerebral, stroke, both due to giant cell arteritis. 
In the first case, the short corticosteroid treatment did not prevent the 
fatal outcome. Ihe second case illustrates that polymyalgia rheumatica is a 
clinical manifestation of GCA and that severe arteritis in vital arteries 
can occur during a flare-up of the arteritis. 
Microscopic examination of the coronary arteries is not routinely performed 
at autopsies and the true incidence of GCA in the coronary arteries is thus 
not known. The prevalence of GCA in cardiological practice is unkncwn and 
the disease has been described as a "cardiological blind spot" (54). A few 
case reports of fatal myocardial infarctions have been published previously 
(22, 86, 96, 104). 
Aortic_areurysm 
Ohe risk of sudden death due to GCA in the aorta with rupture of an aneurysm 
is illustrated by two cases. In one of them (case 3) the diagnosis of GCA 
was not established until autopsy. Before admission to hospital she had ex­
perienced increased fatigue and fever for some months. The other patient had 
been on corticosteroid treatment for two months when during a flare-up of 
the disease, she suddenly developed chest pain and died of a dissecting 
aneurysm of the aorta. The flare-up was only indicated by an elevation of 
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Table IV Soaaaiy of causes of death and microsocpical findings in different 
arteries in nine fatal cases of GCA 
(0 = not examined; - no inflammation; + slight, ++ moderate; 
+++ severe inflammation) 
Case Patient Cause of Temporal Coronary Aorta and Cerebral 
Age Sex death artery artery braches arteries 
(biopsy) 
1  7 3  F  M y o c a r d i a l  + + + + + +  0  
infarction 
2 85 F îfyocardial - +++ + ++ 
infarction 
3 85 F Dissecting 
aneurysm of 
the aorta 
4 79 F Dissecting 
aneurysm of 
the aorta 
5 75 F Cerebral 
stroke 
6 69 M Cerebral 
stroke 
7 76 F Cerebral 
stroke 
8 87 F Cerebral 
stroke 
9 75 F Cerebral 
stroke 
ESR, with no headache or muscular discomfort. The possibility of GCA in the 
aorta was not realised until the patient suddenly died of a ruptured 
aneurysm 14 days after admission to hospital. 
In the first case, fever and fatigue were the only symptoms until the 
aneurysm developed. The patient's delay may have contributed to the fatal 
course. The second case shows that the ESR is a valuable aid to detection of 
flare-ups of GCA and that aortic aneurysm is an important differential 
diagnosis in a GCA patient with chest pain. 
The first report of aortitis causal by GCA was given in 1937 by Sproul and 
Hawthorne (132). Further evidence of GCA in the aorta was presented by 
Gilmour in 1941 (40). Hamrin (45) and Östberg (147) found aortic arch 
syntaame in 14 cut of 93 (15%) patients with GCA. At the Mayo Clinic, 
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involvement of the aorta or its major branches was found in 34 out of 248 
(14%) patients with GCA (73). Three patients with aortitis died of aortic 
rupture in that series. 
Cerebrale ischaemia 
Death due to cerebral ischaemia in connection with GCA is illustrated by 
five cases. One wctnan had been treated with corticosteroids for six years 
under the diagnosis of polymyalgia rheumatica and suffered hemiparesis 
during a flare-up of the disease. The flare-up was indicated by muscular 
pain in her back and upper limbs for about six months. The other patients 
developed their cerebral isdiaemia before corticosteroids were given or 
after less than two weeks of treatment. In one of the patients the diagnosis 
was not established until after death. One of the patients had a normal ESR 
despite an intense arteritis, probably due to a myeloproliferative disorder 
together with the GCA. These cases draw attention to the possibility of GCA 
in a patient with signs of cerebral ischaemia and raised acute inflammatory 
phase reactants. 
With the exception of irtpaired vision, neurological abnormalities caused by 
GCA are rare (51). Patients with synptcsns indicating vertebral artery 
involvement with brainstem lesions have been described (97). GCA in the 
cerebral arteries was reviewed in 1972 by Wilkinson arid Russel (138). They 
found eight cases in the literature and reported four deaths resulting frcm 
GCA among their own cases. Arteritis was found in the vertebral, ophthalmic 
and posterior ciliary arteries. The carotids and central retinal arteries 
were less catmonly involved. They observed a sharply defined upper border of 
the arteritic process about 5 mm above the point of dural perforation. The 
ophthalmic artery was also involved only outside the dura. Our findings of 
arteritis of varying severity in intracranial parts of arteries in six 
patients (case 2 and 4-8) are not in accordance with the opinion that GCA is 
only an extracranial arteritis. However, in case 9 arteritis was found 
only extracranially. Chronic arteritis of the intracranial internal carotid 
arteries was described as early as in 1941 by Gilmour (40). Arteritis in the 
circle of Willis was reported in 1968 by Kjeldsen and Reske-Nilsen (72). 
Crcnpton has reported arteritis in the chiasmatic and pituitary arteries 
(28). 
None of our nine patients with fatal GCA were receiving adequate corticoste­
roid maintenance treatment. The ischaemic catastroph.ies started before or 
during the first weeks of corticosteroid treatment in seven of the patients. 
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The two patients with polymyalgia rheumatica known for three and six years 
respectively had elevated ESR and symptoms indicating insufficient control 
of the arteritic process. 
Fram previous studies, we knew that there are about 40 new cases of GCA 
annually in Göteborg (11). The nine fatal cases were seen during a period of 
seven years, during which about 280 cases of GCA are estimated to have been 
diagnosed. Systematic collection of fatal cases was not done and nine fatal 
cases of 280 may thus be considered a minimum figure. 
longtterm mortality in_GÇA 
In the long-term follcw-up study of 90 corticosteroid- treated patients with 
GCA, the expected and observed mortality rates were as shewn in table V. 
After five years, the mortality was lower than expected. This difference is 
significant (p < 0.05). After 10 years, the difference was not statistically 
significant. 
Table V Observed mortality in a series of orginally 90 patients with GCA 
(68 wemen and 22 mm) oanpared with expected mortality based on 
data fron the official SwBdish statistics 
Number of deaths 
Observed Expected 
Years frcm 
diaanosis women men all wranen men all 
5 8 3 11* 13 7 20 
10 22 11 33 13 30 43 
* p < 0.05 two-sided test with a Poisson distributed test variable 
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Table VI Observed and expected numbers of deaths among 42 patients with 
giant œil arteritis divided into three main groups of diseases. 
Observed Expected deaths 
Causes of death All men wcsnen All men women 
Vascular diseases 25 6 19 26 8 18 
Malignant diseases 7 4 3 10 3 7 
Infections 7 4 3 4 1 3 
In table VI we cxsrpare the observed number of deaths from vascular, 
malignant and infectious diseases with the expected numbers of deaths in the 
general population of the same age and sex in the same period of time. The 
mortality rates in the three grctçis of diseases were not increased in our 
patients. 
Mortality rates among GCA patients similar to those in the general popula­
tion have been found in studies frcm the Mayo Clinic, USA (26, 47, 58), 
Scotland (64), Denmark (17, 77) and France (41, 42). One study, based on 
patients with GCA treated at the Departments of Ophthalmology and Neurology 
at a Lemon hospital (43), has shewn an increased mortality among wcsnen but 
not among men. 
Our conclusion is that, although. GCA can be a cause of death through 
involvement of vital arteries, fatal complications of GCA are so rare in 
well-treated patients that they do not influence the overall mortality rate. 
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oacxiBicws 
Hie mononuclear cell infiltration in the arterial wall of GCA patients 
is mainly ccnpesed of T-helper lymphocytes and macrophages. 
About 15 - 40 % of the infiltrating T lyirphocytes express HLA-ER 
antigen in situ, indicating imnunological activation. 
In the blood of GCA patients, on average 6 per cent of the T lympho­
cytes express HLA-ER antigen before treatment with prednisolone. 
The number of T-helper cells expressing HLA-ER antigen is not altered 
after 6-10 days of treatment with prednisolone. 
Arterial smooth muscle cells in GCA patients do not express HLA-ER 
antigen, in contrast to observations in specimens from patients with 
atherosclerosis. 
In peripheral blood, the proportions of T lymphocytes, T-helper and T-
siçpressor lymphocytes were within the normal range in untreated GCA 
patients. 
GCA can be a cause of death by involvement of coronary and cerebral 
arteries and the aorta. 
Corticosteroid treatment in GCA does not increase the mortality or 
morbidity but inproves quality of life and reduces suffering in GCA 
patients. 
The median duration of corticosteroid treatment in GCA was five years. 
A quarter of the surviving patients were still on treatment after nine 
years. 
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